Daily, systemic injections of a positive AMPA-type glutamate receptor modulator (ampakine) have been shown to reduce synaptic plasticity defects in rodent models of aging and early-stage Huntington's disease (HD). Here we report that long-term ampakine treatment markedly slows the progression of striatal neuropathology and locomotor dysfunction in the R6/2 HD mouse model. Remarkably, these effects were produced by an ampakine, CX929, with a short half-life. Injected once daily for 4-7 weeks, the compound increased protein levels of brain-derived neurotrophic factor (BDNF) in the neocortex and striatum of R6/2 but not wild-type mice. Moreover, ampakine treatments prevented the decrease in total striatal area, blocked the loss of striatal DARPP-32 immunoreactivity and reduced by 36% the size of intra-nuclear huntingtin aggregates in R6/2 striatum. The CX929 treatments also markedly improved motor performance of R6/2 mice on several measures (rotarod, vertical pole descent) but did not influence body weight or lifespan. These findings describe a minimally invasive, pharmacologically plausible strategy for treatment of HD and, potentially, other neuropathological diseases.
Introduction
Ampakines are centrally active, small molecule compounds that slow deactivation and desensitization kinetics of AMPA-type glutamate receptors (AMPARs). Thus, the compounds prolong the opening of ligand bound AMPARs and increase the size and duration of fast, excitatory postsynaptic potentials (EPSPs) (Lynch, 2006) . Recent work has shown that a relatively short series of daily ampakine injections rescues hippocampal synaptic plasticity in rodent models of aging (Rex et al., 2006) , low estrogen levels (Kramar et al., 2010 ) and Huntington's disease (HD) (Simmons et al., 2009 ). In the latter case, treatment of CAG140 knock-in mice with a short half-life ampakine (CX929) also reduced memory deficits associated with early-stage HD. Since testing in these experiments was performed one day after the last injection, the positive results can be ascribed to long-term changes initiated by the ampakine. Related to this point, excitatory drive is known to modulate the expression of several neurotrophic factors including BDNF (Gall and Lauterborn, 2000) , a releasable neurotrophin that plays a pivotal role in long-term potentiation, a form of synaptic plasticity thought to underlie memory (Bramham and Messaoud, 2005; Lynch et al., 2007a; Rex et al., 2007) . Through effects on AMPAR-mediated fast EPSPs, ampakines increase BDNF levels (Lauterborn et al., 2003) and thereby establish conditions that promote synaptic plasticity.
The above findings raise the question of whether prolonging the transcriptional effects of ampakine treatment can slow the progression of HD. While mechanisms underlying the onset and development of HD phenotypes are uncertain, evidence suggests that transcriptional dysregulation and BDNF deficits are important contributors (Canals et al., 2004; Cha, 2000; Sugars and Rubinsztein, 2003; Zuccato and Cattaneo, 2007, 2009 ). This view is reinforced by evidence that BDNF transgene expression reduces motor impairments and striatal neuropathology in HD-model R6/1 mice (Gharami et al., 2008) . The above described short-term ampakine treatments that rescued synaptic plasticity did not improve the modest motor abnormalities (e.g., movement speed) found in young adult CAG140 mice (Simmons et al., 2009 ), but this result may not be predictive of outcomes using longer drug treatments or HD mice with more severe motor impairments. The present studies addressed these issues and, specifically, tested if chronic ampakine treatments can sustain elevated BDNF levels and slow the progression of HD pathology. Neurobiology of Disease 41 (2011) 436-444 
